Advertisement

Thyrotoxicosis Caused by Functioning Metastases of Differentiated Thyroid Cancer

  • Gülin Uçmak
  • Burcu Esen Akkaş
Chapter

Abstract

Differentiated thyroid cancer is a malignant disease with favorable prognosis. The rate of distant metastases is rare. In general, metastases of well-differentiated thyroid cancer carry the main biological features of the thyroid cells such as Na-I symporter gene expression and thyroglobulin synthesis, since the cell does not transfer to an undifferentiated form. However, thyroid hormone synthesis by distant metastasis is uncommon. However, rarely hyperfunctioning distant metastases from DTC after total thyroidectomy can be seen and may result in hyperthyroidism or euthyroidism. In this chapter, the clinical management of a patient presenting with thyrotoxicosis due to hyperfunctioning bone metastases of thyroid cancer is discussed.

Keywords

Hyperfunctioning bone metastases Differentiated thyroid cancer Thyrotoxicosis Radioiodine therapy Antithyroid therapy 

References

  1. 1.
    Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol. 2010;22:395–404.  https://doi.org/10.1016/j.clon.2010.05.00.CrossRefGoogle Scholar
  2. 2.
    Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 1996;37:598–605.PubMedGoogle Scholar
  3. 3.
    Leiter L, Seidlin SM, Marinelli LD. Adenocarcinoma of the thyroid with hyperthyroidism and functional metastases. J Clin Endocrinol Metab. 1946;6:247–51.CrossRefGoogle Scholar
  4. 4.
    Haq M, Hyer S, Flux G, Cook G, Harmer C. Differentiated thyroid cancer presenting with thyrotoxicosis due to functioning metastases. Br J Radiol. 2007;80:38–43.CrossRefGoogle Scholar
  5. 5.
    Basaria S, Salvatori RJ. Thyrotoxicosis due to metastatic papillary thyroid cancer in a patient with Graves’ disease. J Endocrinol Invest. 2002;25:639–42.CrossRefGoogle Scholar
  6. 6.
    Yoshimura Noh J, Mimura T, Kawano M, Hamada N, Ito K. Appearance of TSH receptor antibody and hyperthyroidism associated with metastatic thyroid cancer after total thyroidectomy. Endocr J. 1997;44:855–9.CrossRefGoogle Scholar
  7. 7.
    Miyauchi A, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, et al. 3,5,3′-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma. J Clin Endocrinol Metab. 2008;93:2239–42.  https://doi.org/10.1210/jc.2007-2282.CrossRefPubMedGoogle Scholar
  8. 8.
    Salvatori M, Saletnich I, Rufini V, Dottorini ME, Corsello SM, Troncone L, et al. Severe thyrotoxicosis due to functioning pulmonary metastases of well-differentiated thyroid cancer. J Nucl Med. 1998;39:1202–7.PubMedGoogle Scholar
  9. 9.
    Nishihara E, Amino N, Miyauchi A. Fractionated radioiodine therapy for hyperthyroidism caused by wide spread metastatic follicular thyroid carcinoma. Thyroid. 2010;20:569–70.  https://doi.org/10.1089/thy.2009.0460.CrossRefPubMedGoogle Scholar
  10. 10.
    Paul SJ, Sisson JC. Thyrotoxicosis caused by thyroid cancer. Endocrinol Metab Clin N Am. 1990;19:593–612.CrossRefGoogle Scholar
  11. 11.
    Rotman-Pikielny P, Reynolds JC, Barker WC, Yen PM, Skarulis MC, Sarlis NJ. Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. J Clin Endocrinol Metab. 2000;85:237–44.PubMedGoogle Scholar
  12. 12.
    Lee JI, Chung YJ, Park SJ, Ryu HS, Cho BY. Euthyroid status after total thyroidectomy due to functioning lung metastases from a clear cell variant of papillary thyroid carcinoma. Thyroid. 2012;22:1084–7.  https://doi.org/10.1089/thy.2011.0437.CrossRefPubMedGoogle Scholar
  13. 13.
    Cerletty JM, Listwan WJ. Hyperthyroidism due to functioning metastatic thyroid carcinoma. Precipitation of thyroid storm with therapeutic radioactive iodine. JAMA. 1979;242:269–70.CrossRefGoogle Scholar
  14. 14.
    Wilber JF, Utiger RD. The effect of glucocorticoids on thyrotropin secretion. J Clin Invest. 1969;48:2096–103.CrossRefGoogle Scholar
  15. 15.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.  https://doi.org/10.1089/thy.2015.0020.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Qiu ZL, Shen CT, Luo QY. Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy. Thyroid. 2015;25:229–37.  https://doi.org/10.1089/thy.2014.0233.CrossRefPubMedGoogle Scholar
  17. 17.
    Hindié E, Mellière D, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C, et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging. 2003;30:974–81.CrossRefGoogle Scholar
  18. 18.
    Sisson JC. Practical dosimetry of 131I in patients with thyroid carcinoma. Cancer Biother Radiopharm. 2002;17:101–5.CrossRefGoogle Scholar
  19. 19.
    Wexler JA. Approach to the thyroid cancer patient with bone metastases. J Clin Endocrinol Metab. 2011;96:2296–307.  https://doi.org/10.1210/jc.2010-1996.CrossRefPubMedGoogle Scholar
  20. 20.
    Satcher RL, Lin P, Harun N, Feng L, Moon BS, Lewis VO. Surgical management of appendicular skeletal metastases in thyroid carcinoma. Int J Surg Oncol. 2012;2012:417086.  https://doi.org/10.1155/2012/417086.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, European Association of Nuclear Medicine (EANM), et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59.  https://doi.org/10.1007/s00259-008-0883-1.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Gülin Uçmak
    • 1
  • Burcu Esen Akkaş
    • 1
  1. 1.Department of Nuclear MedicineUniversity of Health Sciences (SBÜ) Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalAnkaraTurkey

Personalised recommendations